Study of IKS04 for advanced cancers that express CA242
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called IKS04 for people with advanced colorectal, bile duct, stomach, or pancreatic cancer that has not responded to other treatments. The drug targets a protein called CA242 found on some cancer cells, and the study aims to see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the colon/rectum, bile ducts, stomach/esophagus, or pancreas that has spread or cannot be removed.
- Your cancer has gotten worse after previous treatments, and no other standard treatment is available or suitable for you.
- You have not had more than 5 prior lines of cancer treatment.
- You must be willing to provide a tumor sample (fresh biopsy or stored tissue) to check for CA242 protein.
- Your blood counts and liver/kidney function must be within certain limits (e.g., platelets ≥ 100,000, hemoglobin ≥ 9.0 g/dL).
- You are generally able to care for yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.